ACT-128800 in Psoriasis (Q64679865)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ACT-128800 in Psoriasis |
clinical trial |
Statements
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800, an S1P1 Receptor Agonist, Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis (English)
0 references
October 2008
0 references
July 2009
0 references
66
0 references
18 year
0 references
60 year
0 references